ArticleChemMedChem2026
Structural and Functional Insights Into (S)-5'-C-Guanidinopropyl Uridine-Modified Oligonucleotides With 2'-O-Methyl and 2'-Fluoro Substitutions for RNAi Therapeutics.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Guanidinium moieties are important structural motifs for improving the physicochemical and biological properties of oligonucleotides. Here, two novel uridine analogs, (S)-5'-C-guanidinopropyl-2'-O-methyluridine (5'-Gp-2'-MoU, 2) and (S)-5'-C-guanidinopropyl-2'-fluorouridine (5'-Gp-2'-FU, 3), were synthesized and incorporated into RNA oligonucleotides. Thermal denaturation studies revealed that single incorporation of 2 slightly reduced duplex stability, whereas 3 produced modest stabilization; however, multiple incorporations markedly decreased melting temperatures, indicating cumulative destabilization. Thermodynamic analyses showed that this effect was primarily enthalpy-driven and partially compensated by favorable entropy contributions. Circular dichroism spectroscopy confirmed preservation of the A-form helical structure, although slight reductions in negative band intensity suggested localized conformational perturbations. siRNAs containing terminal or overhang modifications retained typical A-form signatures without detectable spectral changes. Mismatch discrimination studies demonstrated enhanced sequence selectivity, particularly against U:U and U:G mismatches. Serum stability assays further revealed substantially improved nuclease resistance, with 5'-Gp-2'-MoU (2) exhibiting the highest stability, comparable to the previously reported 5'-Ap-2'-MoU (1). Moreover, KNTC2-targeting siRNAs containing these modifications maintained potent gene-silencing activity in HCT116 cells under lipofection conditions, demonstrating compatibility with RNA-induced silencing complex (RISC) function. These findings identify 5'-guanidinopropyl-modified uridine analogs as promising nucleoside modifications for improving the stability and therapeutic potential of RNA-based therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.